^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

    Excerpt:
    ...- Documented presence of KRAS mutation...
    Trial ID:
    NCT03681483
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

    Excerpt:
    ...- Known KRAS G12C mutation...
    Trial ID:
    NCT05375994
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

    Published date:
    05/30/2017
    Excerpt:
    Among the 10 KRAS-mutant NSCLC patients, tumour regression was seen in 6/10 (60 %), of which 3/10 (30 %) were partial responses. Two of these patients had maintained response for over 1 year and one patient is still on study after 30 cycles.
    DOI:
    10.1200/JCO.2017.35.15_suppl.2506
    Trial ID:
    DDU RAF/MEK